[go: up one dir, main page]

HUE043001T2 - Hematológiai malignómák kezelése anti-CXCR4 antitesttel - Google Patents

Hematológiai malignómák kezelése anti-CXCR4 antitesttel

Info

Publication number
HUE043001T2
HUE043001T2 HUE12787343A HUE12787343A HUE043001T2 HU E043001 T2 HUE043001 T2 HU E043001T2 HU E12787343 A HUE12787343 A HU E12787343A HU E12787343 A HUE12787343 A HU E12787343A HU E043001 T2 HUE043001 T2 HU E043001T2
Authority
HU
Hungary
Prior art keywords
treatment
hematological malignancies
cxcr4 antibody
cxcr4
antibody
Prior art date
Application number
HUE12787343A
Other languages
English (en)
Inventor
Michelle R Kuhne
Chin Pan
Josephine M Cardarelli
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE043001T2 publication Critical patent/HUE043001T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE12787343A 2011-11-09 2012-11-09 Hematológiai malignómák kezelése anti-CXCR4 antitesttel HUE043001T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
HUE043001T2 true HUE043001T2 (hu) 2019-07-29

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12787343A HUE043001T2 (hu) 2011-11-09 2012-11-09 Hematológiai malignómák kezelése anti-CXCR4 antitesttel

Country Status (24)

Country Link
US (2) US10428151B2 (hu)
EP (1) EP2776032B1 (hu)
JP (1) JP6541350B2 (hu)
KR (1) KR102024957B1 (hu)
CN (1) CN104039320B (hu)
AU (1) AU2012335553B2 (hu)
BR (1) BR112014011144A2 (hu)
CA (1) CA2855155A1 (hu)
CY (1) CY1121331T1 (hu)
DK (1) DK2776032T3 (hu)
EA (1) EA026153B1 (hu)
ES (1) ES2705001T3 (hu)
HR (1) HRP20182183T1 (hu)
HU (1) HUE043001T2 (hu)
IL (1) IL232517B (hu)
LT (1) LT2776032T (hu)
MX (1) MX357100B (hu)
PL (1) PL2776032T3 (hu)
PT (1) PT2776032T (hu)
RS (1) RS58102B1 (hu)
SG (1) SG11201401386XA (hu)
SI (1) SI2776032T1 (hu)
SM (1) SMT201900026T1 (hu)
WO (1) WO2013071068A2 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027165T2 (hu) * 2006-10-02 2016-08-29 Squibb & Sons Llc Emberi antitestek, amelyek kötnek CXCR4-et, és felhasználásaik
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
AU2014318614B2 (en) * 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CN105899536A (zh) * 2013-11-06 2016-08-24 百时美施贵宝公司 用抗cxcr4抗体治疗c1013g/cxcr4相关的华氏巨球蛋白血症
CA2930326C (en) 2013-12-06 2022-09-06 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3572425A1 (en) 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
US10066014B2 (en) 2014-02-06 2018-09-04 Yeda Research And Development Co. Ltd. Anti CD84 antibodies, compositions comprising same and uses thereof
CN106794219A (zh) * 2014-02-19 2017-05-31 北京迈康斯德医药技术有限公司 趋化因子受体拮抗体及其联合疗法
AU2016206191B2 (en) * 2015-01-09 2017-08-03 Adalta Limited CXCR4 binding molecules
RS60753B1 (sr) 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
EA201792522A1 (ru) 2015-06-12 2018-05-31 Бристол-Майерс Сквибб Компани Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
KR20180063885A (ko) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
US20180353472A1 (en) * 2015-11-09 2018-12-13 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
EP3419645B1 (en) * 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
SG11201809669RA (en) 2016-05-20 2018-11-29 Biohaven Pharm Holding Co Ltd Use of glutamate modulating agents with immunotherapies to treat cancer
JP2019528241A (ja) * 2016-06-16 2019-10-10 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクCentre National De La Recherche Scientifique インターフェロンレベルを低下させるのに有用な化合物
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018143938A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
TWI693074B (zh) * 2017-02-21 2020-05-11 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
MA50056A (fr) 2017-03-31 2020-02-05 Bristol Myers Squibb Co Procédés de traitement de tumeur
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
WO2019113456A1 (en) * 2017-12-08 2019-06-13 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
JP2022532930A (ja) 2019-05-23 2022-07-20 ブリストル-マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
TW202444754A (zh) * 2023-01-30 2024-11-16 英商凱麥博有限公司 抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2117953C (en) 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7674618B2 (en) 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
EP1871807B1 (en) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
ME02450B (me) 2006-02-28 2016-09-20 Pharma Mar Sa POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA
HUE027165T2 (hu) * 2006-10-02 2016-08-29 Squibb & Sons Llc Emberi antitestek, amelyek kötnek CXCR4-et, és felhasználásaik
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP2297206A1 (en) * 2008-05-14 2011-03-23 Eli Lilly And Company Anti-cxcr4 antibodies
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
CN102369011A (zh) * 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
DK2433124T3 (en) * 2009-05-19 2017-06-19 Vivia Biotech Sl PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
BR112013003823A2 (pt) 2010-08-20 2016-06-28 Cerulean Pharma Inc conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados

Also Published As

Publication number Publication date
SI2776032T1 (sl) 2018-12-31
HRP20182183T1 (hr) 2019-02-22
IL232517B (en) 2018-05-31
KR20140093945A (ko) 2014-07-29
DK2776032T3 (en) 2019-02-04
IL232517A0 (en) 2014-06-30
AU2012335553A1 (en) 2014-07-03
MX2014005267A (es) 2014-07-28
SMT201900026T1 (it) 2019-05-10
AU2012335553B2 (en) 2017-09-21
CN104039320B (zh) 2019-10-15
SG11201401386XA (en) 2014-10-30
EA201490957A1 (ru) 2014-08-29
WO2013071068A3 (en) 2013-07-18
US20200231683A1 (en) 2020-07-23
LT2776032T (lt) 2018-12-10
KR102024957B1 (ko) 2019-09-24
ES2705001T3 (es) 2019-03-21
CA2855155A1 (en) 2013-05-16
EA026153B1 (ru) 2017-03-31
BR112014011144A2 (pt) 2017-05-16
MX357100B (es) 2018-06-26
RS58102B1 (sr) 2019-02-28
JP2014533279A (ja) 2014-12-11
US20140322208A1 (en) 2014-10-30
WO2013071068A2 (en) 2013-05-16
PT2776032T (pt) 2019-01-21
CN104039320A (zh) 2014-09-10
PL2776032T3 (pl) 2019-03-29
CY1121331T1 (el) 2020-05-29
JP6541350B2 (ja) 2019-07-10
EP2776032A2 (en) 2014-09-17
US10428151B2 (en) 2019-10-01
EP2776032B1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
HUE043001T2 (hu) Hematológiai malignómák kezelése anti-CXCR4 antitesttel
HUS2300021I1 (hu) Anti-IL-36R antitestek
HK1255608A1 (zh) 抗htra1抗體及使用方法
CO6811812A2 (es) Anticuerpo anti-b7-h3
EP2761554A4 (en) PAYMENTS IN SOCIAL PROXIMITY
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
EP2692387A4 (en) CATHETER ARRANGEMENT
EP2743171A4 (en) LIQUID NATURAL GAS VEHICLES
CR20140127A (es) Anticuerpo anti-abtcr
DK2717941T3 (da) Behandling af cancer
BR112014005359A2 (pt) prendedor de grampo - estalar de fechar
IL230657A0 (en) Compounds for the treatment of addiction
CO6890075A2 (es) Alcoholimetro calibrable
PL2663506T3 (pl) Zamknięcie
IL231061A0 (en) Antibacterial compounds and methods for use
BR112013032044A2 (pt) antiprurítico
EP2643019A4 (en) ANTIBODIES AGAINST NOTUM PECTINACETYLESTERASE
CO6841994A2 (es) Anticuerpos
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
EP2934499A4 (en) INHIBITION OF TUMOR GROWTH AND METASTASES
DK2607881T3 (da) Koncentrationsapparat
FIU20110150U0 (fi) Viuluhihna
UA22849S (uk) Гітара
UA22461S (uk) Деталь фасонна компресійна-цанга
UA22462S (uk) Деталь фасонна компресійна-фланець